The US Supreme Court’s elimination of the Chevron doctrine of judicial deference is expected to invite more legal challenges to Food and Drug Administration decisions based primarily on interpretations of regulation or statute, but have less impact on the agency’s scientific determinations, such as drug reviews.
Deference No More: More Challenges Against US FDA After Supreme Court Tosses Chevron Doctrine?
The Supreme Court’s 6-3 ruling is expected to have a minimal impact on drug approvals and other scientific determinations, but matters steeped in the interpretation of regulation and statute, such as marketing exclusivity, could face a heightened risk of challenge, legal experts say.